A Combined Phase 0/2 "Trigger" Trial Evaluating Pamiparib or Olaparib with Concurrent Radiotherapy in Patients with Newly-Diagnosed or Recurrent Glioblastoma

W.R. Kennedy, Y.W. Chang, J. Jiang, J. Molloy, C. Pennington-Krygier, J. Harmon, A. Hong, J. Wanebo, K. Braun,M.A. Garcia,I.J. Barani Jr,W. Yoo, A. Tovmasyan,A.C. Tien, J. Li,S. Mehta,N. Sanai

International journal of radiation oncology, biology, physics（2023）

引用 0|浏览4

暂无评分

摘要

Pamiparib achieved pharmacologically-relevant concentrations in nonenhancing GBM tissue and suppressed induction of PAR levels ex vivo post-radiation. The majority of patients with MGMT-unmethylated GBM advanced to the phase 2 portion of the trial, and pamiparib was generally well-tolerated in these patients.

查看译文

关键词

trial evaluating pamiparib,concurrent radiotherapy,olaparib,newly-diagnosed

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要